Exhibit 3371 · Website

ACM: Drug manufacturer Pfizer to discontinue its steering pricing structure for Enbrel following discussions with ACM

ACM

… a clause that enabled Pfizer to significantly reduce the discount applied to future volumes if the purchased quantities decreased by more than a pre-specified percentage. This created the risk of a substantial financial barrier emerging for hospitals to switch drugs. …

1 double space marked in red. Copy the quote and you'll get the real spaces too.

Screenshot of ACM: Drug manufacturer Pfizer to discontinue its steering pricing structure for Enbrel following discussions with ACM, with the double space marked in red. — Open the full-size photo in a new tab.